Bone Marrow Diseases
Welcome,         Profile    Billing    Logout  
 186 Companies   244 Products   244 Products   91 Mechanisms of Action   17 Trials   2576 News 


12345678910111213...5253»
  • ||||||||||  IRX5183 / Io Therap
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (clinicaltrials.gov) -  Apr 22, 2019   
    P1/2,  N=13, Terminated, 
    Active, not recruiting --> Completed N=40 --> 13 | Trial completion date: Dec 2021 --> Aug 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Aug 2018; Study drug supply expired and could not be renewed.
  • ||||||||||  Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
    Trial completion:  Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) (clinicaltrials.gov) -  Apr 20, 2019   
    P3,  N=260, Completed, 
    N=40 --> 13 | Trial completion date: Dec 2021 --> Aug 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Aug 2018; Study drug supply expired and could not be renewed. Active, not recruiting --> Completed
  • ||||||||||  Jakafi (ruxolitinib) / Incyte
    Trial completion, Trial completion date, Trial primary completion date:  Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) -  Apr 20, 2019   
    P1,  N=31, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Feb 2021 --> Apr 2019 | Trial primary completion date: Feb 2020 --> Apr 2019
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Enrollment change, Trial completion date, Trial termination, Post-transplantation:  Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT (clinicaltrials.gov) -  Apr 5, 2019   
    P2,  N=32, Terminated, 
    N=12 --> 7 | Trial completion date: Apr 2021 --> Mar 2019 | Recruiting --> Terminated | Trial primary completion date: Apr 2020 --> Mar 2019; Lack of funding N=60 --> 32 | Trial completion date: Jul 2020 --> Apr 2019 | Suspended --> Terminated; Poor recruitment
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
    Trial completion, Post-transplantation:  PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis (clinicaltrials.gov) -  Apr 4, 2019   
    P1/2,  N=20, Completed, 
    N=60 --> 32 | Trial completion date: Jul 2020 --> Apr 2019 | Suspended --> Terminated; Poor recruitment Active, not recruiting --> Completed
  • ||||||||||  Trial completion date, Trial primary completion date:  MPN: Registry of Philadelphia-Negative Myeloproliferative Neoplasms (clinicaltrials.gov) -  Apr 2, 2019   
    P=N/A,  N=500, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Apr 2020 --> Apr 2025 | Trial primary completion date: Dec 2018 --> Dec 2022
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (clinicaltrials.gov) -  Apr 2, 2019   
    P=N/A,  N=23, Terminated, 
    Trial completion date: Apr 2020 --> Apr 2025 | Trial primary completion date: Dec 2018 --> Dec 2022 N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Trial completion:  Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (clinicaltrials.gov) -  Mar 5, 2019   
    P2,  N=92, Completed, 
    N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. Active, not recruiting --> Completed
  • ||||||||||  Jakafi (ruxolitinib) / Incyte, Farydak (panobinostat) / Secura Bio
    Trial completion, Trial completion date, Trial primary completion date, Epigenetic controller:  Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) (clinicaltrials.gov) -  Mar 4, 2019   
    P1/2,  N=20, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> May 2018 | Trial primary completion date: Feb 2019 --> May 2018
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy:  Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML (clinicaltrials.gov) -  Feb 28, 2019   
    P1/2,  N=49, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> May 2018 | Trial primary completion date: Feb 2019 --> May 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jul 2018
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
    Enrollment change, Trial termination:  Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) -  Feb 26, 2019   
    P2,  N=20, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> May 2016 N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections.
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome (clinicaltrials.gov) -  Jan 28, 2019   
    P1/2,  N=96, Completed, 
    Completed --> Terminated; No bone lesions detected and poor accrual Active, not recruiting --> Completed | N=52 --> 96 | Trial completion date: Apr 2019 --> Dec 2018 | Trial primary completion date: Apr 2019 --> Dec 2018
  • ||||||||||  Trial completion, Preclinical, Trial completion date, Trial primary completion date:  HEMASTEM: Development of an in Vitro Hematopoietic Culture System and Application to Myelodysplastic Syndromes. (clinicaltrials.gov) -  Jan 23, 2019   
    P=N/A,  N=35, Completed, 
    Active, not recruiting --> Completed | N=52 --> 96 | Trial completion date: Apr 2019 --> Dec 2018 | Trial primary completion date: Apr 2019 --> Dec 2018 Recruiting --> Completed | Trial completion date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2018 --> Jan 2018
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase
    Enrollment change, Trial completion date, Trial termination:  DANIN: Dasatinib Versus Nilotinib for Treatment Na (clinicaltrials.gov) -  Jan 23, 2019   
    P3,  N=10, Terminated, 
    Recruiting --> Completed | Trial completion date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2018 --> Jan 2018 N=50 --> 10 | Trial completion date: Aug 2022 --> Sep 2018 | Recruiting --> Terminated; Protocol Deviation
  • ||||||||||  zoledronic acid / Generic mfg.
    Trial completion date, Trial primary completion date, Head-to-Head:  Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer (clinicaltrials.gov) -  Jan 17, 2019   
    P4,  N=280, Not yet recruiting, 
    Active, not recruiting --> Completed Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Sep 2020 --> Sep 2021
  • ||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) -  Jan 15, 2019   
    P2,  N=11, Completed, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Sep 2020 --> Sep 2021 Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017
  • ||||||||||  pioglitazone / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia (clinicaltrials.gov) -  Jan 9, 2019   
    P2,  N=9, Terminated, 
    Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017 N=26 --> 9 | Trial completion date: May 2021 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: May 2021 --> Jul 2018
  • ||||||||||  PLX51107 / Daiichi Sankyo
    Trial completion date, Trial termination, Trial primary completion date, Metastases:  A Study of PLX51107 in Advanced Malignancies (clinicaltrials.gov) -  Dec 24, 2018   
    P1b/2a,  N=50, Terminated, 
    N=40 --> 10 Trial completion date: May 2019 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2019 --> Sep 2018; Business Decision
  • ||||||||||  Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Correlative Biomarker Study in Patients With Myeloproliferative Disorders (clinicaltrials.gov) -  Dec 13, 2018   
    P=N/A,  N=592, Completed, 
    Trial completion date: May 2019 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2019 --> Sep 2018; Business Decision Recruiting --> Completed | N=860 --> 592 | Trial completion date: Jun 2019 --> Jul 2018 | Trial primary completion date: Jun 2019 --> Jul 2018
  • ||||||||||  Enrollment closed, Enrollment change:  A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome (clinicaltrials.gov) -  Dec 4, 2018   
    P1/2,  N=52, Active, not recruiting, 
    Recruiting --> Completed | N=860 --> 592 | Trial completion date: Jun 2019 --> Jul 2018 | Trial primary completion date: Jun 2019 --> Jul 2018 Recruiting --> Active, not recruiting | N=40 --> 52
  • ||||||||||  Trial termination:  Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) -  Nov 16, 2018   
    P1,  N=9, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Feb 2018 Active, not recruiting --> Terminated; Loss of funding
  • ||||||||||  bortezomib / Generic mfg.
    Trial termination:  Bortezomib in Treating Patients With Chronic Myelogenous Leukemia (clinicaltrials.gov) -  Nov 15, 2018   
    P2,  N=7, Terminated, 
    Active, not recruiting --> Terminated; Loss of funding Completed --> Terminated; Lack of efficacy
  • ||||||||||  Trial termination:  New York Blood Center National Cord Blood Program (clinicaltrials.gov) -  Nov 2, 2018   
    P1,  N=4476, Terminated, 
    Trial primary completion date: May 2018 --> Dec 2017 Recruiting --> Terminated; Study NCT01656603 supersedes this study; FDA IND 6637
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov) -  Nov 2, 2018   
    P2,  N=7, Terminated, 
    Recruiting --> Terminated; Study NCT01656603 supersedes this study; FDA IND 6637 N=100 --> 7 | Trial completion date: Oct 2023 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Jul 2018; Original principal investigator left institution
  • ||||||||||  talacotuzumab (JNJ-56022473) / J&J
    Enrollment change, Trial termination, Trial primary completion date:  SAMBA: Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY (clinicaltrials.gov) -  Oct 25, 2018   
    P2,  N=25, Terminated, 
    Recruiting --> Completed | N=50 --> 15 N=43 --> 25 | Suspended --> Terminated | Trial primary completion date: Jun 2018 --> Oct 2018; Enrollement was stopped due to a recommendation by the IDMC/FDA for a parallel clinical trial with TALA, where potentielly no efficancy could be determined.
  • ||||||||||  lenalidomide / Generic mfg.
    Enrollment change, Trial termination:  Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (clinicaltrials.gov) -  Oct 18, 2018   
    P2,  N=32, Terminated, 
    N=43 --> 25 | Suspended --> Terminated | Trial primary completion date: Jun 2018 --> Oct 2018; Enrollement was stopped due to a recommendation by the IDMC/FDA for a parallel clinical trial with TALA, where potentielly no efficancy could be determined. N=48 --> 32 | Active, not recruiting --> Terminated; Lack of efficacy
  • ||||||||||  cyclophosphamide / Generic mfg.
    Trial completion, Phase classification, Trial completion date, Trial primary completion date, Post-transplantation:  Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide (clinicaltrials.gov) -  Oct 17, 2018   
    P1,  N=127, Completed, 
    N=48 --> 32 | Active, not recruiting --> Terminated; Lack of efficacy Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 | Trial completion date: Jun 2022 --> Mar 2018 | Trial primary completion date: Jun 2019 --> Mar 2018